Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil

Tarcia Nogueira Ferreira Gomes, Fabio Silva de Azevedo, Marjorie Argollo, Sender Jankiel Miszputen, Orlando Ambrogini Jr Disciplina de Gastroenterologia, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, BrazilCorrespondence: Tarcia Nogueira F...

Full description

Bibliographic Details
Main Authors: Gomes TNF, Azevedo FS, Argollo M, Miszputen SJ, Ambrogini Jr O
Format: Article
Language:English
Published: Dove Medical Press 2021-03-01
Series:Clinical and Experimental Gastroenterology
Subjects:
Online Access:https://www.dovepress.com/clinical-and-demographic-profile-of-inflammatory-bowel-disease-patient-peer-reviewed-article-CEG
_version_ 1819140649850503168
author Gomes TNF
Azevedo FS
Argollo M
Miszputen SJ
Ambrogini Jr O
author_facet Gomes TNF
Azevedo FS
Argollo M
Miszputen SJ
Ambrogini Jr O
author_sort Gomes TNF
collection DOAJ
description Tarcia Nogueira Ferreira Gomes, Fabio Silva de Azevedo, Marjorie Argollo, Sender Jankiel Miszputen, Orlando Ambrogini Jr Disciplina de Gastroenterologia, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, BrazilCorrespondence: Tarcia Nogueira Ferreira Gomes Rua Percílio Neto, 131, Vila Gumercindo, CEP 04131-080, São Paulo-SP, BrazilTel +55 11 94991 3883Email tarcia.nogueira@gmail.comBackground: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract with an increasing incidence in developing countries.Purpose: To report clinical and demographic data of CD and UC at a referral center for inflammatory bowel disease (IBD) in São Paulo.Patients and Methods: We conducted a retrospective cross-sectional study on adult patients with established IBD. Demographic and clinical data were obtained by medical records analysis from the IBD Outpatient Clinic of EPM-UNIFESP, from October 1997 to October 2017.Results: Of 658 patients included, 355 had UC (54%) and 303 had CD (46%). UC was more prevalent in women than CD (219 [61.7%] vs 152 [50.2%], p=0.003). The median time between the onset of symptoms and diagnosis was 13 (5– 38) months, with a longer duration for CD patients. CD mostly affected the ileocolonic location (47.9%). CD patients with stricture, fistula and/or perianal disease (213/303, 70.3%) were younger at diagnosis, had a longer disease duration, higher rates of corticosteroid, immunomodulatory, and biological therapy, hospitalization, and referral to surgery, compared to patients without complication. Extensive colitis was the most common extension of UC (50.6%), which was more frequently associated with younger age at diagnosis, hepatobiliary disease, increased need for hospitalization, higher use of immunomodulatory, and biologic therapy, compared to patients with less extensive disease. In the last 5 years, CD patients were more frequently on biologic and/or immunomodulatory (70.9%) therapy, and UC patients often received salicylates (78.1%) and immunomodulatory (28.1%) treatments. There was a consistent reduction in salicylate usage for CD in the last 5 years compared to the total period of follow-up.Conclusion: Despite the increasing incidence, we highlight the diagnostic delay and a more complicated CD and extensive UC in this cohort, reflecting a high need for immunomodulatory and biological treatment, hospitalization, and surgery.Keywords: Crohn’s disease, epidemiology, inflammatory bowel disease, ulcerative colitis
first_indexed 2024-12-22T11:41:55Z
format Article
id doaj.art-3dad46cad40c4ce6aea7977517eccd8e
institution Directory Open Access Journal
issn 1178-7023
language English
last_indexed 2024-12-22T11:41:55Z
publishDate 2021-03-01
publisher Dove Medical Press
record_format Article
series Clinical and Experimental Gastroenterology
spelling doaj.art-3dad46cad40c4ce6aea7977517eccd8e2022-12-21T18:27:15ZengDove Medical PressClinical and Experimental Gastroenterology1178-70232021-03-01Volume 149110263160Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, BrazilGomes TNFAzevedo FSArgollo MMiszputen SJAmbrogini Jr OTarcia Nogueira Ferreira Gomes, Fabio Silva de Azevedo, Marjorie Argollo, Sender Jankiel Miszputen, Orlando Ambrogini Jr Disciplina de Gastroenterologia, Escola Paulista de Medicina, Universidade Federal de São Paulo (UNIFESP), São Paulo, BrazilCorrespondence: Tarcia Nogueira Ferreira Gomes Rua Percílio Neto, 131, Vila Gumercindo, CEP 04131-080, São Paulo-SP, BrazilTel +55 11 94991 3883Email tarcia.nogueira@gmail.comBackground: Crohn’s disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the gastrointestinal tract with an increasing incidence in developing countries.Purpose: To report clinical and demographic data of CD and UC at a referral center for inflammatory bowel disease (IBD) in São Paulo.Patients and Methods: We conducted a retrospective cross-sectional study on adult patients with established IBD. Demographic and clinical data were obtained by medical records analysis from the IBD Outpatient Clinic of EPM-UNIFESP, from October 1997 to October 2017.Results: Of 658 patients included, 355 had UC (54%) and 303 had CD (46%). UC was more prevalent in women than CD (219 [61.7%] vs 152 [50.2%], p=0.003). The median time between the onset of symptoms and diagnosis was 13 (5– 38) months, with a longer duration for CD patients. CD mostly affected the ileocolonic location (47.9%). CD patients with stricture, fistula and/or perianal disease (213/303, 70.3%) were younger at diagnosis, had a longer disease duration, higher rates of corticosteroid, immunomodulatory, and biological therapy, hospitalization, and referral to surgery, compared to patients without complication. Extensive colitis was the most common extension of UC (50.6%), which was more frequently associated with younger age at diagnosis, hepatobiliary disease, increased need for hospitalization, higher use of immunomodulatory, and biologic therapy, compared to patients with less extensive disease. In the last 5 years, CD patients were more frequently on biologic and/or immunomodulatory (70.9%) therapy, and UC patients often received salicylates (78.1%) and immunomodulatory (28.1%) treatments. There was a consistent reduction in salicylate usage for CD in the last 5 years compared to the total period of follow-up.Conclusion: Despite the increasing incidence, we highlight the diagnostic delay and a more complicated CD and extensive UC in this cohort, reflecting a high need for immunomodulatory and biological treatment, hospitalization, and surgery.Keywords: Crohn’s disease, epidemiology, inflammatory bowel disease, ulcerative colitishttps://www.dovepress.com/clinical-and-demographic-profile-of-inflammatory-bowel-disease-patient-peer-reviewed-article-CEGcrohn’s diseaseepidemiologyinflammatory bowel diseaseulcerative colitis
spellingShingle Gomes TNF
Azevedo FS
Argollo M
Miszputen SJ
Ambrogini Jr O
Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil
Clinical and Experimental Gastroenterology
crohn’s disease
epidemiology
inflammatory bowel disease
ulcerative colitis
title Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil
title_full Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil
title_fullStr Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil
title_full_unstemmed Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil
title_short Clinical and Demographic Profile of Inflammatory Bowel Disease Patients in a Reference Center of São Paulo, Brazil
title_sort clinical and demographic profile of inflammatory bowel disease patients in a reference center of s atilde o paulo brazil
topic crohn’s disease
epidemiology
inflammatory bowel disease
ulcerative colitis
url https://www.dovepress.com/clinical-and-demographic-profile-of-inflammatory-bowel-disease-patient-peer-reviewed-article-CEG
work_keys_str_mv AT gomestnf clinicalanddemographicprofileofinflammatoryboweldiseasepatientsinareferencecenterofsatildeopaulobrazil
AT azevedofs clinicalanddemographicprofileofinflammatoryboweldiseasepatientsinareferencecenterofsatildeopaulobrazil
AT argollom clinicalanddemographicprofileofinflammatoryboweldiseasepatientsinareferencecenterofsatildeopaulobrazil
AT miszputensj clinicalanddemographicprofileofinflammatoryboweldiseasepatientsinareferencecenterofsatildeopaulobrazil
AT ambroginijro clinicalanddemographicprofileofinflammatoryboweldiseasepatientsinareferencecenterofsatildeopaulobrazil